Saxagliptin Market - Forecast(2021 - 2026)

Report Code: HCR 21994 Report Format: PDF + Excel (Delivery in 48 Hrs)
Saxagliptin Market size is valued at $ 184Mn by 2019, and is anticipated to grow at a CAGR of 3.7% during the forecast period 2020-2025. The Saxagliptin Market growth rate is attributed to the increasing incidence of diabetes with changing lifestyle, reduced physical exercise that lead to diabetes, complexities in alternative therapies for diabetes, and high obesity. Saxagliptin is an oral anti-diabetic agent known as DPP IV inhibitor. This enzyme helps in suppressing the release of glucagon. Saxagliptin is used for medication of diabetes, as to boost the amount of postprandial insulin in the body produced after meal. From improvement’s made in regulatory framework to rise in number of product innovations and R&D activities in the field of diabetes therapeutics is anticipated to propel the Saxagliptin Market during the forecast period 2020-2025.  
Report Coverage

The report: “Saxagliptin Market Forecast (2020-2025)”, by Industry ARC, covers an in-depth analysis of the following segments of the Saxagliptin Market. 

By Dosage: 2.5 Mg, 5 Mg
By Age Group: Adult, Geriatric
By Sales Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Geography: North America, Asia Pacific, Europe, Rest of World

Key Takeaways
  • North America dominated the Saxagliptin Market with a share of 37% in the year 2019.        
  • The factors such as Increasing prevalence of obesity, increasing sedentary lifestyle and junk food habits thereby increasing incidence of type II diabetes are amongst the major factor projected to impel growth of Saxagliptin Market.
  • Increased government funding for innovative R&Ds and increasing healthcare awareness are the key factors owing to the growth in the segment during forecast period 2020-2025.
Dosage Type - Segment Analysis

2.5 Mg held the largest share in the market over 5 Mg owing to single, one-step dose adjustment in patients with moderate to severe renal impairment. The segment is estimated to grow at a CAGR of 2.8% Also ketoconazole, a strong CYP3A4/5 inhibitor, increased saxagliptin exposure to the dose of ONGLYZA should be limited to 2.5 mg when co-administered with a strong CYP3A4/5 inhibitor otherwise it might lead to side effects like including joint pain, unusual skin blisters, signs of heart failure (such as shortness of breath, swelling ankles/feet, unusual tiredness, unusual/sudden weight gain).
By Geography - Segment Analysis

North America dominated the Saxagliptin Market with a share of 39% in 2019. The application of Saxagliptin has grown rapidly over the last few years owing to the growing awareness among patients owing to large number of aging population and increasing prevalence of type II diabetes. With rising government funding and increasing healthcare expenditure on R&D are to cater the Saxagliptin Market in the forecast period of 2020-2025.

Drivers – Saxagliptin Market
  • Increase in Sedentary Lifestyle   
The rise in demand of various products increased with rise in the type II diabetes cases owing to increasing sedentary lifestyle and junk food habits amongst various age groups and also the pool of patients belonging to the geriatric category is large which is considered as a Saxagliptin key driver of the market during the forecast period 2020-2025. 
Challenges – Saxagliptin Market
  • Strict regulations for approval of drugs
The major challenge for the market is the unavailability substitutes for treatment of diabetes with emerging large pool of geriatric patients. The stringent rules and regulations regarding the approval of drugs prior to distribution and sales is the major problem for some of the regions which is to hinder the market growth in the forecast period of 2020-2025. 

Saxagliptin Industry Outlook

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Saxagliptin Market. In 2019, Saxagliptin Market share is fragmented by the top ten players present in the market. Saxagliptin Market top 10 companies are Bristol-Myers Squibb Company, AstraZeneca Plc, Jubilant Life Sciences Limited, Hetero Drugs Limited, Farmak JSC, Centaur Pharmaceuticals, Teva Pharmaceutical Industries, Prajna Generics, Dr Reddy’s Laboratories Limited and others.

Acquisitions/Product Launches
  • In February 28, 2017 Astra Zeneca announced that FDA approved once-daily QTERN® (dapagliflozin and saxagliptin) tablets for adults with type-2 diabetes as an adjunct to diet and exercise to improve glycemic (blood sugar level) control in adults with type-2 diabetes who have inadequate control with dapagliflozin (10mg) or who are already treated with dapagliflozin and saxagliptin.
  • In May 29, 2015 Dr Reddy’s Laboratories Limited and AstraZeneca Pharma India Limited entered into a distribution agreement for saxagliptin and its fixed dose combination with metformin, in Type 2 Diabetes by offering innovative treatment options across the Indian market.
1. Saxagliptin Market Overview
    1.1 Definitions and Scope
2. Saxagliptin Market - Executive Summary
    2.1 Market Revenue and Key Trends by Company
    2.2 Key trends by Dosage
    2.3 Key trends by Age Group
    2.4 Key trends by Sales Channel
    2.5 Key trends by Geography
3. Saxagliptin Market – Comparative Analysis
    3.1 Product Benchmarking – Key Companies
    3.2 Financial Analysis – Key Companies
    3.3 Market Value Split by Key Companies
    3.4 Patent Analysis – Key Companies
    3.5 Pricing Analysis
4. Saxagliptin Market - Startup Companies Scenario (Premium)
    4.1 Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Saxagliptin Market – Industry Market Entry Scenario Premium (Premium)
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing business index
    5.3 Case Studies of Successful Ventures
6. Saxagliptin Market Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters five force model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes 
7. Saxagliptin Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Saxagliptin Market – By Dosage (Market Size –$Million/$Billion)
    8.1 2.5 Mg
    8.2 5 Mg
9. Saxagliptin Market – By Age Group (Market Size –$Million/$Billion)
    9.1 Adult
    9.2 Geriatric
10. Saxagliptin Market – By Sales Channel (Market Size –$Million/$Billion)
    10.1 Hospital Pharmacies 
    10.2 Retail Pharmacies
    10.3 Online Pharmacies
    10.4 Others
11. Saxagliptin Market - By Geography (Market Size –$Million/$Billion)
    11.1 North America
        11.1.1 U.S.
        11.1.2 Canada
        11.1.3 Mexico
    11.2 Europe
        11.2.1 U.K.
        11.2.2 Germany
        11.2.3 France
        11.2.4 Italy
        11.2.5 Spain
        11.2.6 Rest of Europe
    11.3 Asia-Pacific
        11.3.1 China
        11.3.2 India
        11.3.3 Japan
        11.3.4 South Korea
        11.3.5 Australia & New Zealand
        11.3.6 Rest of Asia-Pacific
    11.4 Rest of the World
        11.4.1 Middle East
        11.4.2 Africa
        11.4.3 South America
12. Saxagliptin Market - Entropy
13. Saxagliptin Market – Industry/Segment Competition Landscape (Premium) 
    13.1 Market Share Analysis
        13.1.1 Global Market Share – Key Companies
        13.1.2 Market Share by Region – Key companies
        13.1.3 Market Share by Countries – Key Companies
        13.1.4 Best Practices for Companies
14. Saxagliptin Market – Key Company List by Country Premium (Premium)
15. Saxagliptin Market Company Analysis
    15.1 Company 1
    15.2 Company 2
    15.3 Company 3
    15.4 Company 4
    15.5 Company 5
    15.6 Company 6
    15.7 Company 7
    15.8 Company 8
    15.9 Company 9
    15.10 Company 10 and more
"*Financials for private companies would be provided on a best efforts basis”.


1.Global Saxagliptin Market, By Dosage Market 2019-2024 ($M)
1.1 2.5 Mg Market 2019-2024 ($M) - Global Industry Research
1.2 5 Mg Market 2019-2024 ($M) - Global Industry Research
2.Global Saxagliptin Market, By Dosage Market 2019-2024 (Volume/Units)
2.1 2.5 Mg Market 2019-2024 (Volume/Units) - Global Industry Research
2.2 5 Mg Market 2019-2024 (Volume/Units) - Global Industry Research
3.North America Saxagliptin Market, By Dosage Market 2019-2024 ($M)
3.1 2.5 Mg Market 2019-2024 ($M) - Regional Industry Research
3.2 5 Mg Market 2019-2024 ($M) - Regional Industry Research
4.South America Saxagliptin Market, By Dosage Market 2019-2024 ($M)
4.1 2.5 Mg Market 2019-2024 ($M) - Regional Industry Research
4.2 5 Mg Market 2019-2024 ($M) - Regional Industry Research
5.Europe Saxagliptin Market, By Dosage Market 2019-2024 ($M)
5.1 2.5 Mg Market 2019-2024 ($M) - Regional Industry Research
5.2 5 Mg Market 2019-2024 ($M) - Regional Industry Research
6.APAC Saxagliptin Market, By Dosage Market 2019-2024 ($M)
6.1 2.5 Mg Market 2019-2024 ($M) - Regional Industry Research
6.2 5 Mg Market 2019-2024 ($M) - Regional Industry Research
7.MENA Saxagliptin Market, By Dosage Market 2019-2024 ($M)
7.1 2.5 Mg Market 2019-2024 ($M) - Regional Industry Research
7.2 5 Mg Market 2019-2024 ($M) - Regional Industry Research


1.US Saxagliptin Market Revenue, 2019-2024 ($M)
2.Canada Saxagliptin Market Revenue, 2019-2024 ($M)
3.Mexico Saxagliptin Market Revenue, 2019-2024 ($M)
4.Brazil Saxagliptin Market Revenue, 2019-2024 ($M)
5.Argentina Saxagliptin Market Revenue, 2019-2024 ($M)
6.Peru Saxagliptin Market Revenue, 2019-2024 ($M)
7.Colombia Saxagliptin Market Revenue, 2019-2024 ($M)
8.Chile Saxagliptin Market Revenue, 2019-2024 ($M)
9.Rest of South America Saxagliptin Market Revenue, 2019-2024 ($M)
10.UK Saxagliptin Market Revenue, 2019-2024 ($M)
11.Germany Saxagliptin Market Revenue, 2019-2024 ($M)
12.France Saxagliptin Market Revenue, 2019-2024 ($M)
13.Italy Saxagliptin Market Revenue, 2019-2024 ($M)
14.Spain Saxagliptin Market Revenue, 2019-2024 ($M)
15.Rest of Europe Saxagliptin Market Revenue, 2019-2024 ($M)
16.China Saxagliptin Market Revenue, 2019-2024 ($M)
17.India Saxagliptin Market Revenue, 2019-2024 ($M)
18.Japan Saxagliptin Market Revenue, 2019-2024 ($M)
19.South Korea Saxagliptin Market Revenue, 2019-2024 ($M)
20.South Africa Saxagliptin Market Revenue, 2019-2024 ($M)
21.North America Saxagliptin By Application
22.South America Saxagliptin By Application
23.Europe Saxagliptin By Application
24.APAC Saxagliptin By Application
25.MENA Saxagliptin By Application
26.Bristol-Myers Squibb Company, Sales /Revenue, 2015-2018 ($Mn/$Bn)
27.Astrazeneca Plc, Sales /Revenue, 2015-2018 ($Mn/$Bn)